论文部分内容阅读
目的：提高放射免疫显像（ｒａｄｉｏｉｍｍｕｎｏｉｍａｇｉｎｇ，ＲＩＩ）质量，建立卵巢癌预定位放射显像技术。方法：将合成的环二乙基三胺五乙酸（ｃｙｃｌｉｃｄｉｅｔｈｙｌｅｎｅｔｒｉａｍｉｎｅｐｅｎｔａａｃｅｔｉｃａｃｉｄ，ｃＤＴＰＡ）与卵巢癌单抗ＣＯＣ１８３Ｂ２进行偶联，Ｓｅｐｈａｄｅｘ分离纯化后，采用免疫组织化学染色及细胞放射自显影对偶联物进行活性测定。将偶联的ＣＯＣ１８３Ｂ２ｃＤＴＰＡ或ＩｇＧ分别经腹腔注入荷人卵巢癌裸鼠腹水瘤模型体内，４８ｈ后，将还原９９ｍＴｃ淋洗液经腹腔注入体内，６ｈ后进行ＲＩＩ。显像后，体外称重并测量瘤及其他正常组织放射性活性，计算瘤与非瘤放射性比值（Ｔ／ＮＴ）。结果：（１）ＣＯＣ１８３Ｂ２ｃＤＴＰＡ与浆液性卵巢癌组织免疫组化染色呈阳性；细胞放射自显影结果可见卵巢癌ＳＫＯＶ３细胞膜周围呈环状显影，提示偶联后单抗仍保留了较好的免疫活性。（２）注射还原９９ｍＴｃ６ｈ后ＲＩＩ，可见实验组荷瘤裸鼠腹腔有特异放射性聚集；而对照荷瘤裸鼠腹腔无特异放射性聚集。实验组各器官Ｔ／ＮＴ值高于对照组，两者差异有显著性（Ｐ＜０．０５）。结论：ｃＤＴＰＡ偶联ＣＯＣ１８３Ｂ２单抗进行卵巢癌预定位放射免疫显像?
OBJECTIVE: To improve the quality of radioimmunoimaging (RII) and to establish a preoperative radiological imaging technique for ovarian cancer. Methods: The synthesized cyclic diethylenetriaminepentaacetic acid (cDTPA) was coupled with ovarian cancer monoclonal antibody COC183B2. After separation by Sephadex, the activity of the conjugate was determined by immunohistochemistry and cell autoradiography. The coupled COC183B2 cDTPA or IgG were injected intraperitoneally into the model of human ovarian cancer ascites tumor in nude mice, after 48h, the reduced 99mTc eluent was intraperitoneally injected into the body, RII 6h. After imaging, the tumor and other normal tissues were weighed and the radioactivity of the tumor and other normal tissues was measured. The tumor to non-tumor radioactivity ratio (T / NT) was calculated. Results: (1) Immunohistochemical staining of COC183B2cDTPA and serous ovarian cancer tissues showed positive results. Cell autoradiography showed a circular development around the cell membrane of ovarian cancer SKOV3, suggesting that monoclonal antibody still retains a good immune response active. (2) The RII of 99mTc6h after injection reduction showed that the experimental group had specific radioactivity accumulation in the abdominal cavity of nude mice, while the control group had no specific radioactivity accumulation in the abdominal cavity of nude mice. The T / NT value of each organ in the experimental group was higher than that in the control group, the difference was significant (P <0.05). Conclusion: cDTPA conjugate COC183B2 monoclonal antibody for radioimmunoimaging of pre-targeted ovarian cancer?